1. 142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom. (December 2022) Authors: Franks, K.; Ahmed, M.; Smith, D.; Shaw, P.H.; Banna, G.; Cominos, M.; Walther, J.; Talbot, T.; Taylor, P.; Blak, B.; Lindqvist, L.; Paul, S.K.; Vincent, D. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗